Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Melissa, Engle"'
Autor:
Vincent K. Chang, Marjorie Z. Imperial, Patrick P. J. Phillips, Gustavo E. Velásquez, Payam Nahid, Andrew Vernon, Ekaterina V. Kurbatova, Susan Swindells, Richard E. Chaisson, Susan E. Dorman, John L. Johnson, Marc Weiner, Erin E. Sizemore, William Whitworth, Wendy Carr, Kia E. Bryant, Deron Burton, Kelly E. Dooley, Melissa Engle, Pheona Nsubuga, Andreas H. Diacon, Nguyen Viet Nhung, Rodney Dawson, Radojka M. Savic, AIDS Clinical Trial Group, Tuberculosis Trials Consortium
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-12 (2024)
Abstract The Phase 3 randomized controlled trial, TBTC Study 31/ACTG A5349 (NCT02410772) demonstrated that a 4-month rifapentine-moxifloxacin regimen for drug-susceptible pulmonary tuberculosis was safe and effective. The primary efficacy outcome was
Externí odkaz:
https://doaj.org/article/de940f5d4bbc4e00aaa1dfc2d65e721a
Autor:
Anne E. Purfield, Nigel A. Scott, Samuel Pierre, Madeleine Lourens, Richard E. Chaisson, Melissa Engle, Payam Nahid, Erin Sizemore, Patrick P. J. Phillips, Ziyaad Waja, Kelly E. Dooley, Susan Swindells, Marc H Weiner, Ekaterina V. Kurbatova, Kim Narunsky, Radojka M. Savic, Susan E. Dorman, Sandy Nerette, Nhung Viet Nguyen, Wadzanai Samaneka, Ha T.T. Phan, James Hakim, Andrew Vernon, Thuong H. Pham, Grace Muzanyi, Stefan V. Goldberg, Justin Shenje, John L. Johnson, Neil A. Martinson, Kia E Bryant, Ian Sanne
Publikováno v:
The New England journal of medicine, vol 384, iss 18
BackgroundRifapentine-based regimens have potent antimycobacterial activity that may allow for a shorter course in patients with drug-susceptible pulmonary tuberculosis.MethodsIn an open-label, phase 3, randomized, controlled trial involving persons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3229ece147fe062e786e2a34a8ab15fd
https://escholarship.org/uc/item/30c34231
https://escholarship.org/uc/item/30c34231
Autor:
Kuo Wei Chiu, Kathleen Robergeau-Hunt, Pamela Fedrick, Anne E. Purfield, Mascha Elskamp, Yan Yuan, Nicole E Brown, Kim Narunsky, William C. Whitworth, Kimberley N Chapman Hedges, Ekaterina V. Kurbatova, Melissa Fagley, Erin Sizemore, Melissa Engle, Joanita Nassali, Cynthia Allen-Blige, Kumar Batra, Jessica N Ricaldi, Howard Davis, Kia E Bryant, Ha Phan, Mimi Phan
Publikováno v:
Contemp Clin Trials
Introduction With the growing use of online study management systems and rapid availability of data, timely data review and quality assessments are necessary to ensure proper clinical trial implementation. In this report we describe central monitorin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffebd0194dfb50408522d91d1abf0c15
https://pubmed.ncbi.nlm.nih.gov/33713841
https://pubmed.ncbi.nlm.nih.gov/33713841
Autor:
Melissa Engle, P. Nsubuga, Rada M. Savic, Jon Gelfond, Teresa L. Johnson-Pais, John L. Johnson, Susan E. Dorman, Erin Bliven-Sizemore, Marc H Weiner, William C. Whitworth
Publikováno v:
J Antimicrob Chemother
Background Rifapentine exposure is associated with bactericidal activity against Mycobacterium tuberculosis, but high interindividual variation in plasma concentrations is encountered. Objectives To investigate a genomic association with interindivid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2aec1998ba76fb6e5d2cf86349b32574
https://pubmed.ncbi.nlm.nih.gov/33374006
https://pubmed.ncbi.nlm.nih.gov/33374006
Autor:
William J. Burman, Kelly E. Dooley, Pei-Jean Feng, Michael Chen, Melissa Engle, Stefan V. Goldberg, John L. Johnson, Mark F. Cotton, Nguyen Viet Nhung, Kwok-Chiu Chang, Kathleen Robergeau, Andrew Vernon, Lorna Bozeman, José M. Miró, Courtney V. Fletcher, Ekaterina V. Kurbatova, Anne E. Purfield, April C. Pettit, Patrick P. J. Phillips, Erin Sizemore, Marc H Weiner, Richard E. Chaisson, Erica Lessem, Susan Swindells, Nigel A. Scott, Anthony T. Podany, Susan E. Dorman, Wadzanai Samaneka, Phan Ha, Beverly Metchock, Payam Nahid, Charles M. Heilig
Publikováno v:
Contemp Clin Trials
Introduction Phase 2 clinical trials of tuberculosis treatment have shown that once-daily regimens in which rifampin is replaced by high dose rifapentine have potent antimicrobial activity that may be sufficient to shorten overall treatment duration.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6d0d59beba872c1af6cc8330255f07f
https://doi.org/10.1016/j.cct.2020.105938
https://doi.org/10.1016/j.cct.2020.105938
Autor:
Melissa Engle, Charles A. Peloquin, Mac Kenzie Wr, Jonathan Gelfond, Marc H Weiner, Erin Sizemore, Teresa L. Johnson-Pais, John L. Johnson
Publikováno v:
Antimicrobial Agents and Chemotherapy. 62
Moxifloxacin exhibits concentration-dependent prolongation of human QTc intervals and bactericidal activity against Mycobacterium tuberculosis . However, moxifloxacin plasma concentrations are variable between patients. We evaluated whether human gen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::716d24b2c2cadbf398f247ade0e3f45f
https://doi.org/10.1128/aac.01802-17
https://doi.org/10.1128/aac.01802-17
Autor:
Marc, Weiner, Jon, Gelfond, Teresa L, Johnson-Pais, Melissa, Engle, Charles A, Peloquin, John L, Johnson, Erin E, Sizemore, William R, Mac Kenzie
Publikováno v:
Antimicrobial agents and chemotherapy. 62(5)
Moxifloxacin exhibits concentration-dependent prolongation of human QTc intervals and bactericidal activity against Mycobacterium tuberculosis. However, moxifloxacin plasma concentrations are variable between patients. We evaluated whether human gene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c923c72a089bd8a60517a09cd615da7d
https://pubmed.ncbi.nlm.nih.gov/29463526
https://pubmed.ncbi.nlm.nih.gov/29463526
Autor:
John L. Johnson, Charles A. Peloquin, Kelly E. Dooley, NV Nguyen, Melissa Engle, William C. Whitworth, Radojka M. Savic, Susan E. Dorman, Payam Nahid, William R. MacKenzie, P. Nsubuga, Michael Weiner
Publikováno v:
Clinical pharmacology and therapeutics, vol 102, iss 2
Clinical Pharmacology and Therapeutics
Clinical Pharmacology and Therapeutics
Rifapentine is a highly active antituberculosis antibiotic with treatment-shortening potential; however, exposure-response relations and the dose needed for maximal bactericidal activity have not been established. We used pharmacokinetic/pharmacodyna
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3be0da687955c3afd4fdaae35fea86a3
https://escholarship.org/uc/item/5dt4r0x1
https://escholarship.org/uc/item/5dt4r0x1
Autor:
Marc H Weiner, M. Elsa Villarino, Melissa Engle, Erin E. Bliven, Jonathan Gelfond, Gregory L. Kearns, Susan M. Abdel-Rahman, Thomas J. Prihoda, Nigel A. Scott, Radojka M. Savic, Timothy R. Sterling, Charles A. Peloquin, Diane Wing, William J. Burman, William R. Mac Kenzie
Publikováno v:
Journal of the Pediatric Infectious Diseases Society. 3:132-145
Background In a phase 3, randomized clinical trial (PREVENT TB) of 8053 people with latent tuberculosis infection, 12 once-weekly doses of rifapentine and isoniazid had good efficacy and tolerability. Children received higher rifapentine milligram pe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d32fdd1d157ffd80f6b0d1582993f246
https://doi.org/10.1093/jpids/pit077
https://doi.org/10.1093/jpids/pit077
Autor:
Charles A. Peloquin, Erin Bliven-Sizemore, William J. Burman, Thomas J. Prihoda, John L. Johnson, Marc H Weiner, Chi Cheng Luo, William R. Mac Kenzie, Melissa Engle, Andrew Vernon
Publikováno v:
Antimicrobial Agents and Chemotherapy. 54:4192-4200
Rifampin has concentration-dependent activity against Mycobacterium tuberculosis . However, marked intersubject variation of rifampin concentrations occurs. In this study, we evaluated rifampin pharmacokinetics in relation to tuberculosis, geographic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b7f22390fe7cb052275cef91fb16651
https://doi.org/10.1128/aac.00353-10
https://doi.org/10.1128/aac.00353-10